

Title: Involvement of P2X7 receptors in satellite glial cells of dorsal root ganglia in the BmK I-induced pain model of rats

Running title: P2X7R contributes to pain

Create date: 2019-07-02

<i>Name</i>	<i>Affiliations</i>
Jingjing Zhou	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Danting Feng	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Xiaoxue Zhang	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Chenchen Xia	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Zhiping Zhang	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Jiahao Kang	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China
Research Assistant Professor Zhiyong Tan	1. Department of Pharmacology and Toxicology and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
Bin Wu	1. Laboratory of Neuropharmacology and Neurotoxicology, School of Life science, Shanghai University, Shanghai, China 2. Department of Pharmacology and Toxicology and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States

Corresponding author: Research Assistant Professor Zhiyong Tan <zt2@iupui.edu>

Corresponding author: Bin Wu <bwu1@iu.edu>

Abstract

The P2X7 receptor (P2X7R) plays an important role in inflammatory and neuropathic pain. Our recent study indicated that activation of P2X7R in microglial cells of spinal cord contributes to the inflammatory pain induced by BmK I—the major active compound from *Buthus martensi* Karsch (BmK). In the present study, we further investigated whether P2X7R in satellite glial cells (SGCs) of dorsal root ganglion (DRG) is involved in the BmK I-induced pain in rats. The results found that the expression of P2X7R in SGCs was increased in the ipsilateral side of L4–L5 DRGs after intraplantar injection of BmK I. Moreover, the expression of an inflammatory cytokine IL-1 β was increased in DRG after BmK I injection. Systemic administration of an inhibitor of P2X7R (A-438079) significantly inhibited both spontaneous and evoked nociceptive behaviors induced by BmK I. These results suggest that the P2X7R in SGCs of DRG might contribute to pain induced by toxins that sensitize peripheral sensory nerves.

1 **Involvement of P2X7 receptors in satellite glial cells of dorsal root ganglia in the**
2 **BmK I -induced pain model of rats**

3

4 Jingjing Zhou¹, Danting Feng¹, Xiaoxue Zhang¹, Chenchen Xia¹, Zhiping Zhang¹, Jiahao Kang¹,
5 Zhiyong Tan^{2*}, Bin Wu^{1,2,*}

6

7 ¹, Laboratory of Neuropharmacology and Neurotoxicology, Shanghai University, Shanghai
8 200444, P.R. China; ², Department of Pharmacology and Toxicology and Stark Neurosciences
9 Research Institute, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.

10

11 *Corresponding author

12

13 **Address for Corresponding author:**

14

15 Zhiyong Tan, PhD

16 Research Assistant Professor of Pharmacology and Toxicology

17 Stark Neurosciences Research Institute

18 Indiana University School of Medicine

19 Indiana University – Purdue University Indianapolis

20 320 W. 15th Street, NB-514E

21 Indianapolis, Indiana 46202

22 Phone: (317)278-6310

23 Fax: (317)274-0067

24 E-mail: zt2@iupui.edu

25

26 Bin Wu, PhD

27 Stark Neurosciences Research Institute

28 Indiana University School of Medicine

29 Indiana University – Purdue University Indianapolis

30 320 W. 15th Street, NB-514E

31 Indianapolis, Indiana 46202

32 Phone: (317)7788665

33 E-mail: bwu1@iu.edu

34

35

36

37 **Abstract**

38 The P2X7 receptor (P2X7R) plays an important role in inflammatory and
39 neuropathic pain. Our recent study indicated that activation of P2X7R in microglial
40 cells of spinal cord contributes to the inflammatory pain induced by BmK I ,the major
41 active compound from *Buthusmartensi Karsch* (BmK). In the present study, we
42 further investigated whether P2X7R in satellite glial cells (SGCs) of dorsal root
43 ganglion (DRG) is involved in the BmK I-induced pain in rats. The results found that
44 the expression of P2X7R in SGCs was increased in the ipsilateral side of L4–L5
45 DRGs after intraplantar injection of BmK I. Moreover, the expression of an
46 inflammatory cytokine IL-1 β was increased in DRG after BmK I injection. Systemic
47 administration of an inhibitor of P2X7R (A-438079) significantly inhibited both
48 spontaneous and evoked nociceptive behaviors induced by BmK I. These results
49 suggest that the P2X7R in SGCs of DRG might contribute to pain induced by toxins
50 that sensitize peripheral sensory nerves.

51

52 **Keywords:** Pain, Dorsal root ganglia, Interleukin 1 beta, Satellite glial cell, P2X7
53 receptor, BmK I

54

55

56

57

58

59 **Introduction**

60 Pathological pain is a common symptom of many conditions, and severely
61 reduces quality of life and health status of millions of patients. It has been shown that
62 **adenosine triphosphate (ATP)** receptors play important role in neuropathic and
63 inflammatory pain **conditions** (Chizh and Illes 2001, Burnstock 2009, Burnstock
64 2013). Among the ATP receptors, the P2X7 receptor (P2X7R) can form a large,
65 macromolecular pore upon repetitive or prolonged exposure to high concentrations of
66 ATP (North 2002). Moreover, the P2X7R plays an important role in the initiation and
67 maintenance of inflammatory and neuropathic pain (Chizh and Illes 2001, Sperlagh,
68 Vizi et al. 2006, Skaper, Debetto et al. 2010). Particularly, recent study indicated that
69 activation of P2X7R in microglial cells of spinal cord contributes to the inflammatory
70 pain induced by BmK I, an activator of sodium channel and a major toxin component
71 of the venom of Asian scorpion *Buthusmartensi Karsch* (BmK) (Zhou, Zhang et al.
72 2019). In **dorsal root ganglion** (DRG), P2X7R is selectively expressed in **satellite glial**
73 **cells (SGCs)**, and is involved in the modulation of nociceptive signals in DRGs
74 (North 2002, Liu and Salter 2005, Nakatsuka and Gu 2006, Chen, Zhang et al. 2008).
75 For instance, the P2X7R in SGCs promotes the release of pro-inflammatory cytokines,
76 including tumor necrosis factor alpha (TNF- α), interleukin-1 beta (IL-1 β) and
77 interleukin-6 (IL-6) (Arulkumaran, Unwin et al. 2011).

78 The inflammatory pain behaviors induced by BmK venom include spontaneous

79 pain, ipsilateral thermal hypersensitivity, and bilateral mechanical hypersensitivity in
80 rats (Bai, Liu et al. 2010). The active compound BmK I purified from the venom of
81 the BmK plays a major role in the inflammatory pain caused by the BmK venom (Bai,
82 Zhang et al. 2003, Bai, Liu et al. 2010). The bilateral mechanical hypersensitivity is a
83 characteristic feature of pain induced by BmK I venom or BmK I that highlights the
84 importance of utilizing natural toxins in pain models. The DRG neuron is the primary
85 neuron that transmits noxious stimuli from the periphery to the central nervous system
86 (Basbaum, Bautista et al. 2009). The neuronal soma of DRG neurons communicate
87 bilaterally with their surrounding SGCs in DRGs (Zhang, Chen et al. 2007, Chen,
88 Zhang et al. 2008). However, it is not clear whether or how SGCs might interact with
89 neurons in DRG in the pain model induced by toxins. In the current study, we
90 investigated the role of P2X7R in SGCs of DRG in the BmK I-induced pain model of
91 rat.

92

93 **Materials and Methods**

94 *Experimental animals*

95 Adult male Sprague-Dawley rats (210±10 g) used in this study were provided by
96 Shanghai Experimental Animal Center, Chinese Academy of Sciences. All
97 experiments had been done according to the guidelines of International Association
98 for the Study of Pain (IASP) for pain research in conscious animals. All efforts were
99 made to minimize animal suffering and to reduce the number of animals used.

100 ***Preparation and administration of BmK I***

101 Crude BmK venom was purchased from an individual scorpion culture farm in
102 Henan Province, China. BmK I used in this study was purified from the venom of
103 scorpion BmK following the process described by Ji *et al.* (Ji, Mansuelle et al. 1996),
104 and then assessed by both mass spectrum and high-performance liquid
105 chromatography. Fifty microliters of BmK I (0.2 µg/µL in saline) was intraplantarly
106 (i.pl.) injected into the left hind paw (Jiang, Pang et al. 2013). Saline solution of the
107 same volume was used in control animals.

108 ***Preparation and administration of A-438079***

109 A-438079 (MedChemExpress, Princeton, NJ, USA), an inhibitor of P2X7R was
110 dissolved in saline (30.6mg/ml, 100mM). 100 microliters of A-438079 (15mg/kg) was
111 intraperitoneal injected into rats 30 minutes before BmK I injection.

112 ***Behavioral testing***

113 In the study, behavioral tests were used to evaluate the suppressive effect of
114 A-438079 on BmK I-induced pain responses. The measurement of spontaneous
115 nociceptive responses, paw withdrawal mechanical threshold (PWMT) and paw
116 withdrawal thermal latency (PWTL) were performed according to the methods
117 described by Bai *et al.* (Bai, Zhang et al. 2003).

118 ***Measurement of spontaneous nociceptive behaviors***

119 The test box with a glass floor was placed on a steel frame above the

120 experimental table covered with a mirror. Before administration, rats were placed in
121 the test box separately for habituation. 30 min after the intraperitoneal injection of
122 A-438079, BmK I was injected into the rats' left hind paws. Spontaneous nociceptive
123 behaviors are determined by the number of the injected hind paw flinches during 5
124 min interval for 2 h (Chen, Luo et al. 1999). Evaluation of spontaneous nociceptive
125 behaviors was performed by an experimenter unaware of the experimental condition.

126 *Measurement of PWMT*

127 Mechanical sensitivity was detected by using a series of 10 calibrated von Frey
128 filaments with forces ranging from 0.6 to 26 g (58011, Stoelting Co., Wood Dale,
129 Illinois, U.S.A.). Each filaments were applied bilaterally to hind paws. Each filament
130 was probed for same duration of 2-3 s with an inter-stimulus interval of 10 s. The
131 positive response was indicated by brisk withdrawal and/or flinching. Each subject's
132 **PWMT** was defined as the lowest force that caused at least five withdrawals out of ten
133 consecutive applications (Chen, Luo et al. 1999). Baseline PWMT measures for each
134 subject were taken 24 h prior to testing. Evaluation of PWMT was performed by an
135 experimenter unaware of the experimental condition.

136

137 *Measurement of PWTL*

138 Each subject's **PWTL** to radiant heat stimuli was determined as previously
139 described (Hargreaves, Dubner et al. 1988). Heat stimuli were provided with radiant
140 heat stimulator (RTY-3, Xi'an Fenglan Instrument Factory, Xi an, Shaanxi province,

141 China). The heat source was a high intensity projector halogen lamp bulb (150 W, 24
142 V). For one rat, five stimuli were performed with a stimuli interval of 10 min, and the
143 rat's PWTL was determined by averaging the last three values of the five consecutive
144 stimuli. Baseline PWTL measures were taken 24h before testing. Evaluation of PWTL
145 was performed by an experimenter unaware of the experimental condition.

146

147 *Western blot*

148 At different time points (1h, 2h, 4h, 8h, 24h) after i.p. Bmk I injection, the rats
149 were anesthetized with intraperitoneal injection of sodium pentobarbital (60 mg/kg),
150 while naive rats were considered as control group. The L4–L5 DRGs protein lapping
151 liquids were obtained by homogenization in ice-cold RIPA Lysis Buffer (Beyotime,
152 Shanghai, China). After 30 min ice-water bath and centrifugation at 14000 rpm for 15
153 min, the supernate containing total cellular protein was collected. Then each protein
154 concentrations were measured by Bradford Protein Assay Kit (Beyotime, Shanghai,
155 China). Finally, SDS-PAGE Sample Loading Buffer was mixed into the supernate by
156 proportion until heated for 5 min at boiling water. Protein samples (45 μ g) were
157 separated on 5% SDS-PAGE and blotted on a PVDF membrane (0.45 μ m; Millipore,
158 Billerica, Massachusetts, U.S.A.). The membranes were then incubated in 5% non-fat
159 milk at room temperature for 2 h. The primary antibodies listed in supplement were
160 then individually diluted in PBS with Tween-20 (0.05%PBST) containing 1% BSA
161 and incubated overnight at 4°C.

162 The blots were detected in ECL detection reagent (WBKLS0050; Millipore,
163 Billerica, Massachusetts, U.S.A.) with a fully automatic chemiluminescence image
164 analysis system (Tanon-5200; Tanon Science & Technology Co., Ltd., Shanghai, China).
165 The bands were captured with the image analysis system and quantified using Image J
166 (National Institutes of Health, Bethesda, Maryland, U.S.A.).

167

168 **Immunohistochemistry**

169 Rats were anesthetized and perfused intracardially with 200 mL sterile saline
170 after intraplantar injection of BmK I at different time points (2h, 4h, 8h, and 24h),
171 followed by 400 mL fixative containing 4% paraformaldehyde in 0.1 M phosphate
172 buffer (PBS; pH 7.4). Bilateral DRGs from L4-L5 were post-fixed in 0.1 M PBS
173 containing 20% sucrose for dehydration until precipitates, then DRG tissues were
174 cryoprotected in 0.1 mol/L PBS containing 30% sucrose until they subsided again.
175 Frozen serial coronal sections (14 μ m in thickness) were cut with a Cryostat
176 Microtome (HM525; Thermo Fisher Microm, Walldorf, Germany) and mounted on
177 gelatin-coated glass slides.

178 Frozen sections were air dried and incubated with 5% bovine serum albumin (in
179 PBS) for 1 h at room temperature, followed by incubation with primary antibody
180 diluents overnight at 4 °C. After rinsed in 0.01 M PBS, the sections were incubated
181 with secondary antibodies for 1.5 h. Then DRG sections were rinsed again and
182 coverslipped. The digital images were captured from fluorescent microscopy

183 (LSM710; Carl Zeiss, Jena, Germany) and merged by Image J software. The primary
184 and secondary antibodies are listed in supplement.

185 ***Real-time quantitative polymerase chain reaction***

186 Each 1 h, 2 h, 4 h, 8 h, and 24 h after intraplantar injection of 50 μ l diluted BmK I
187 solution (0.2 μ g/ μ l) into adult male rats (n = 4 for each group), total RNA was isolated
188 from bilateral L4-L5 DRGs with Total RNA Extractor(Trizol) (Sangon Biotech,
189 Shanghai, China). Then the RNA was reverse-transcribed with Prime-Script[®] RT
190 Master Mix (TaKaRa, Dalian, China). Primer sequences targeted to P2X7R were
191 designed by Primer Premier 6.0 software (Premier Biosoft, California, U.S.A.) while
192 the primers for β -actin was designed referring to a previous publication (Qin, Jiang et
193 al. 2017). The primer sequences are listed in supplement.

194 Quantitative PCR was performed by CFX Connect[™] Real-Time PCR System
195 (Bio-Rad, California, U.S.A.) in SYBR[®] remix Ex Taq[™] (TaKaRa, Dalian, China).
196 The P2X7 subtypes mRNA was normalized to the β -actin mRNA level and the data
197 were analyzed using the $2^{-\Delta\Delta C_t}$ method (Adnan, Morton et al. 2011).

198 **Statistical analysis**

199 All results were expressed as mean \pm S.E.M. (standard error of the mean) and
200 analyzed by GraphPad Prism 6 software(GraphPad Software, Inc., La Jolla, California,
201 U.S.A.). Data of immunostaining also used the Image-Pro Plus 6.0 software(Media
202 Cybernetics, Inc. Rockville, Maryland, U.S.A.). The differences between groups were
203 compared by Two-way ANOVA followed by Dunnett's post hoc test. The data of

204 behavior tests were analyzed using One-way ANOVA followed by a Dunnett's post
205 hoc test and Two-way ANOVA followed by a Bonferroni's post hoc test. The relative
206 densities of Western blots were analyzed by one-way ANOVA followed by Dunnett's
207 post hoc test and One-way ANOVA followed by a Tukey's post hoc test, $p < 0.05$ was
208 considered to be statistically significant.

209

210 **3. Results**

211 **3.1 Effects of BmK I on P2X7R in SGCs of DRG**

212 Immunohistochemistry experiments were conducted to study the effects of BmK
213 I on the expression of P2X7R in DRG. Immunoreactivity (IR) for P2X7R was
214 stronger at the ipsilateral DRG of BmK I group (Fig.1B-E, G-J) compared to the
215 control group (Fig.1A,F) following BmK I injection. The increase in the P2X7R
216 reactivity started from 2h after BmK I injection (Fig.1B), peaked at 4h (Fig.1 C),
217 decreased at 8h (Fig.1 D), and further decreased at 24h (Fig.1E). On the other hand,
218 the staining of contralateral P2X7R did not have significant change during the same
219 period (Fig. 1G-J, M).

220 The protein expression levels of the P2X7R in the DRG were further analyzed by
221 Western blot analysis. The expression of P2X7R in the BmK I group was significantly
222 increased compared to the control group. The P2X7R in the ipsilateral dorsal root
223 ganglia was significantly increased at 2, 4, and 8h after BmK I administration (Fig.1
224 K). Compared to the ipsilateral side (Fig.1 K), a significant change of P2X7R

225 expression was only observed at 4 h after BmK I injection at the contralateral side of
226 the dorsal root ganglia (Fig.1 L). Moreover, the increase at 4h after BmK I injection
227 was more than 2x larger at the ipsilateral side compared to contralateral side of DRG.

228 To study if transcriptional mechanism might be involved in the increase of
229 P2X7R receptors, we also performed qPCR experiments to study the mRNA
230 expression of P2X7R. It was observed that mRNA expression of P2X7R was
231 selectively increased at the ipsilateral side, but not the contralateral side of DRG at 4
232 and 8 h after BmK I administration (Fig.1 N&O).

233 To study if the increased P2X7Rs are expressed in the SGCs of DRG, the
234 co-localization of the P2X7R and GFAP (a marker of SGCs) was measured by double
235 immunofluorescence staining. Positive staining of P2X7R was shown in Fig.2 A,D
236 and GFAP was shown in Fig.2 B,E. Confocal microphotography indicated that the
237 P2X7R and GFAP were co-localized in the DRG SGCs (Fig.2 C,F). **The percentage of**
238 **SCGs co-labeled P2X7R and GFAP was 28.6% and 88.8% for control and BmK I**
239 **groups, respectively.**

240

241 **3.2 Effects of BmK I on IL-1 β in DRG.**

242 The immunoreactivity of IL-1 β was studied in DRG 4h after BmK I
243 administration. In the sections of the L4-5 dorsal root ganglia from the control rats
244 (Fig.3 A and B), only few immunoreactivity for IL-1 β could be detected. The
245 immunoreactivity of IL-1 β increased significantly after BmK I administration (Fig.3

246 C-F).

247 The protein expression of IL-1 β in DRG was further detected by Western blot. It
248 was found that IL-1 β was increased at both sides of DRG after BmK I injection (Fig.3
249 G-H). Compared to the control group, a significant increase of IL-1 β was detected at
250 4h after BmK I administration.

251

252 **3.3 Effects of a P2X7R antagonist A-438079 on BmK I-induced pain behaviors**

253 To study the functional relevance of P2X7R in the development of BmK
254 I-induced pain, we examined whether A-438079 reduces the BmK I-induced pain
255 behaviors. We administrated the A-438079 (100 μ M, intraperitoneal) 30 minutes
256 before BmK I or saline administration. Compared to the control group, 100 μ M
257 A-438079 significantly suppressed the spontaneous pain responses (Fig.4 A,B). The
258 suppression of flinches by A-438079 lasted for 2h(Fig.4 A). Furthermore, the BmK
259 I-induced hypersensitivity was also reduced by A-438079. Bilateral mechanical
260 hypersensitivity (Fig.4 C,D) and ipsilateral thermal hypersensitivity (Fig.4 E) were
261 reduced at 4 h and 8h after BmK I administration. However, A-438079 had no effects
262 on the contralateral thermal sensitivity (Fig.4 F).

263 **4. Discussion**

264 DRG neurons produce **primary sensory action potentials** upon peripheral stimuli
265 and transmit **the action potential** signal to the spinal cord .The P2X7 receptor in DRG
266 modulates afferent nerve activation and is involved in both neuropathic (Wu, Ma et al.

267 2017, Xie, Liu et al. 2017) and inflammatory pain **conditions** (Liu, Tao et al. 2017).
268 Our recent study indicates that activation of P2X7R in microglial cells of spinal cord
269 contributes to the inflammatory pain induced by BmK I (Zhou, Zhang et al. 2019). In
270 the present study, we examined the expression of P2X7 receptors in the SGCs of DRG
271 in the BmK I-**induced** pain model.

272 Both mRNA and immunohistochemistry experiments found that the P2X7R was
273 significantly increased at the ipsilateral side, but not contralateral side of DRG. On the
274 other hand, Western blot experiments found that the P2X7R was significantly
275 increased at both the ipsilateral and contralateral side of DRG. However, the increase
276 at the contralateral side was moderate compared to the ipsilateral side. These results
277 suggest that BmK I **induces** profound and preferential increases in the P2X7R at the
278 injection side of DRG. Moreover, the increase in the **P2X7R** was from 2-8 hours after
279 BmK I injection. Therefore, it **is** suggested that BmK I **induces** a transient activation
280 of P2X7 receptors. Double staining experiments found that the P2X7R was
281 co-localized with GFAP suggesting that **BmK I activates** the P2X7R in the SGCs.
282 Taken together, it **is** suggested that BmK I **induces** a transient, ipsilateral side
283 preferentially increase **in the expression** of P2X7R in the SGCs of DRG in rats.

284 **Notably, our results indicate that the BmK I-induced increase in the mRNA**
285 **expression is earlier than that in the protein expression of P2X7R (Fig. 1N&K) This**
286 **phenomenon suggests that a post-transcriptional mechanism that enhances translation**
287 **of P2X7R mRNA might be involved in the early up-regulation of P2X7R protein**
288 **induced by BmK I. On the other hand, the BmK I-induced increase in mRNA peaked**

289 at 8 h while the increase in protein peaked at 4 h (Fig. 1N&K). This result suggests a
290 negative post-transcriptional mechanism might be also involved in the modulation of
291 BmK I on the expression of P2X7R. Interestingly, a brain enriched microRNA,
292 miR-22 was recently identified to control the expression of P2X7R in hippocampus. It
293 can selectively silence the mRNA of P2X7R resulting in the decreased expression of
294 protein, but not mRNA level of P2X7R (Jimenez-Mateos, Arribas-Blazquez et al.
295 2015, Engel, Brennan et al. 2017). It might be suspected that there may be a similar
296 post-transcriptional feedback mechanism in DRG which inhibits the continual
297 increasing of P2X7R protein in the BmK I model.

298 It has been generally assumed that pro-inflammatory cytokines, including IL-1 β
299 and TNF- α , play an important role in the initiation and maintenance of inflammatory
300 (Albuquerque, Fonteles et al. 2017) and neuropathic pain (Wu, Peng et al. 2017, Xie,
301 Liu et al. 2017). It has been demonstrated that P2X7 receptors can mediate the release
302 of IL-1 β (Burnstock and Knight 2018). Our results found that the expression of IL-1 β
303 was increased in the BmK I-induced rats. Therefore, it was suggested that the
304 activation of the P2X7R might lead to the release of IL-1 β in the DRG following
305 BmK I injection. However, our results found that the increase in IL-1 β was similar
306 between ipsilateral and contralateral sides while the increase in P2X7R was
307 preferentially on the ipsilateral side. The results suggest that BmK I-induced
308 up-regulation of P2X7R might preferentially contribute to the release of IL-1 β at the
309 ipsilateral side of DRG, and that there might have other mechanism contributing to
310 the up-regulation of IL-1 β at the contralateral side of DRG.

311 In addition to the increased expression of P2X7R and IL-1 β in DRG, we also
312 found that systemic administration of A-438079 reduced both evoked and
313 spontaneous pain behaviors induced by BmK I. These results suggest that P2X7R in
314 SGCs of DRG might contribute to the pain hypersensitivity in the BmK I –induced
315 pain model. Moreover, our recent study suggested that microglial P2X7R in spinal
316 cord might contribute to the BmK I –induced pain. Therefore, both P2X7R in SGCs
317 of DRG and in microglial cells of spinal cord might contribute to the pain
318 hypersensitivity induced by BmK I.

319 The effects of peripheral SGCs on pain have been studied in the DRG (Hanani,
320 Huang et al. 2002, Hanani 2005). Spontaneous pain activity originating at the injured
321 side or DRG neurons may be a cause of glial activation (Chung and Chung 2002, Xie,
322 Strong et al. 2009). It is well known that the soma of neurons in primary sensory
323 ganglia are tightly enwrapped by SGCs. The SGCs in DRG express P2X7 receptors
324 (Gu, Chen et al. 2010, Chen, Li et al. 2012, Puchalowicz, Baranowska-Bosiacka et al.
325 2015) and can communicate with neurons by signaling molecules. P2X7Rs in SGCs
326 are endogenously active in the DRG (Chen, Zhang et al. 2008, Huang, Gu et al. 2013).
327 Therefore, increased P2X7Rs in SGCs of DRG might contribute to the activation of
328 SGCs following BmK I injection. Activated SGCs might release excitatory
329 neuropeptides such as IL-1 β that can increase the excitability of DRG neurons, and
330 the pain sensitivity in the BmK I pain model.

331 **5. Conclusion**

332 In conclusion, the present study provides first evidence to support an involvement
333 of peripheral P2X7R (expressed in the SGCs in DRG) in the pain induced by a toxin
334 (BmK I).

335

336 **Disclosure statement**

337 No potential conflict of interest was reported by the authors.

338

339

340 **Acknowledgements**

341 This work was supported by grants from National Natural Science Foundation of
342 China (31571032, 31771191). Z.T. was supported by an Indiana Spinal Cord and
343 Brain Injury Research Fund (2017). The authors thank Mrs. Renqi Wu for her
344 technical assistance.

345

346

347 **REFERENCES**

- 348 Adnan, M., G. Morton and S. Hadi (2011). "Analysis of rpoS and bolA gene expression under various
349 stress-induced environments in planktonic and biofilm phase using 2(-Delta Delta CT) method."
350 Molecular and Cellular Biochemistry **357**(1-2):275-282.
- 351 Albuquerque, A. F. M., C. S. R. Fonteles, D. R. do Val, H. V. Chaves, M. M. Bezerra, K. M. A. Pereira, P. G.
352 de Barros Silva, B. B. de Lima, E. C. S. Soares, T. R. Ribeiro and F. W. G. Costa (2017). "Effect of
353 pre-emptive analgesia on clinical parameters and tissue levels of TNF-alpha and IL-1beta in third molar
354 surgery: a triple-blind, randomized, placebo-controlled study." Int J Oral Maxillofac Surg **46**(12):
355 1615-1625.
- 356 Arulkumaran, N., R. J. Unwin and F. W. Tam (2011). "A potential therapeutic role for P2X7 receptor
357 (P2X7R) antagonists in the treatment of inflammatory diseases." Expert Opin Investig Drugs **20**(7):
358 897-915.
- 359 Bai, Z. T., T. Liu, F. Jiang, M. Cheng, X. Y. Pang, L. M. Hua, J. Shi, J. J. Zhou, X. Q. Shu, J. W. Zhang and Y. H.
360 Ji (2010). "Phenotypes and peripheral mechanisms underlying inflammatory pain-related behaviors
361 induced by BmK I, a modulator of sodium channels." Exp Neurol **226**(1): 159-172.
- 362 Bai, Z. T., X. Y. Zhang and Y. H. Ji (2003). "Fos expression in rat spinal cord induced by peripheral
363 injection of BmK I, an alpha-like scorpion neurotoxin." Toxicol Appl Pharmacol **192**(1): 78-85.
- 364 Basbaum, A. I., D. M. Bautista, G. Scherrer and D. Julius (2009). "Cellular and molecular mechanisms of
365 pain." Cell **139**(2): 267-284.
- 366 Burnstock, G. (2009). "Purinergic receptors and pain." Curr Pharm Des **15**(15): 1717-1735.
- 367 Burnstock, G. (2013). "Purinergic mechanisms and pain--an update." Eur J Pharmacol **716**(1-3): 24-40.
- 368 Burnstock, G. and G. E. Knight (2018). "The potential of P2X7 receptors as a therapeutic target,
369 including inflammation and tumour progression." Purinergic Signal **14**(1): 1-18.
- 370 Chen, J., C. Luo, H. Li and H. Chen (1999). "Primary hyperalgesia to mechanical and heat stimuli
371 following subcutaneous bee venom injection into the plantar surface of hindpaw in the conscious rat:
372 a comparative study with the formalin test." Pain **83**(1): 67-76.
- 373 Chen, Y., G. Li and L. Y. Huang (2012). "P2X7 receptors in satellite glial cells mediate high functional
374 expression of P2X3 receptors in immature dorsal root ganglion neurons." Mol Pain **8**:9.
- 375 Chen, Y., X. Zhang, C. Wang, G. Li, Y. Gu and L. Y. Huang (2008). "Activation of P2X7 receptors in glial
376 satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons." Proc
377 Natl Acad Sci U S A **105**(43): 16773-16778.
- 378 Chizh, B. A. and P. Illes (2001). "P2X receptors and nociception." Pharmacol Rev **53**(4): 553-568.
- 379 Chung, J. M. and K. Chung (2002). "Importance of hyperexcitability of DRG neurons in neuropathic
380 pain." Pain Pract **2**(2): 87-97.
- 381 Engel, T., G. P. Brennan, A. Sanz-Rodriguez, M. Alves, E. Beamer, O. Watters, D. C. Henshall and E. M.
382 Jimenez-Mateos (2017). "A calcium-sensitive feed-forward loop regulating the expression of the
383 ATP-gated purinergic P2X7 receptor via specificity protein 1 and microRNA-22." Biochim Biophys Acta
384 Mol Cell Res **1864**(2): 255-266.
- 385 Gu, Y., Y. Chen, X. Zhang, G. W. Li, C. Wang and L. Y. Huang (2010). "Neuronal soma-satellite glial cell
386 interactions in sensory ganglia and the participation of purinergic receptors." Neuron Glia Biol **6**(1):
387 53-62.
- 388 Hanani, M. (2005). "Satellite glial cells in sensory ganglia: from form to function." Brain Res Brain Res
389 Rev **48**(3): 457-476.

390 Hanani, M., T. Y. Huang, P. S. Cherkas, M. Ledda and E. Pannese (2002). "Glial cell plasticity in sensory
391 ganglia induced by nerve damage." Neuroscience **114**(2): 279-283.

392 Hargreaves, K., R. Dubner, F. Brown, C. Flores and J. Joris (1988). "A new and sensitive method for
393 measuring thermal nociception in cutaneous hyperalgesia." Pain **32**(1): 77-88.

394 Huang, L. Y., Y. Gu and Y. Chen (2013). "Communication between neuronal somata and satellite glial
395 cells in sensory ganglia." Glia **61**(10): 1571-1581.

396 Ji, Y. H., P. Mansuelle, S. Terakawa, C. Kopeyan, N. Yanaihara, K. Hsu and H. Rochat (1996). "Two
397 neurotoxins (BmK I and BmK II) from the venom of the scorpion *Buthus martensi* Karsch: purification,
398 amino acid sequences and assessment of specific activity." Toxicon **34**(9): 987-1001.

399 Jiang, F., X. Y. Pang, Q. S. Niu, L. M. Hua, M. Cheng and Y. H. Ji (2013). "Activation of mammalian target
400 of rapamycin mediates rat pain-related responses induced by BmK I, a sodium channel-specific
401 modulator." Mol Pain **9**: 50.

402 Jimenez-Mateos, E. M., M. Arribas-Blazquez, A. Sanz-Rodriguez, C. Concannon, L. A. Olivos-Ore, C. R.
403 Reschke, C. M. Mooney, C. Mooney, E. Luga, J. Morgan, E. Langa, A. Jimenez-Pacheco, L. F. Silva, G.
404 Mesuret, D. Boison, M. T. Miras-Portugal, M. Letavic, A. R. Artalejo, A. Bhattacharya, M.
405 Diaz-Hernandez, D. C. Henshall and T. Engel (2015). "microRNA targeting of the P2X7 purinoceptor
406 opposes a contralateral epileptogenic focus in the hippocampus." Sci Rep **5**: 17486.

407 Liu, C., J. Tao, H. Wu, Y. Yang, Q. Chen, Z. Deng, J. Liu and C. Xu (2017). "Effects of lncRNA BC168687
408 siRNA on Diabetic Neuropathic Pain Mediated by P2X7 Receptor on SGCs in DRG of Rats." Biomed Res
409 Int **2017**: 7831251.

410 Liu, X. J. and M. W. Salter (2005). "Purines and pain mechanisms: recent developments." Curr Opin
411 Investig Drugs **6**(1): 65-75.

412 Nakatsuka, T. and J. G. Gu (2006). "P2X purinoceptors and sensory transmission." Pflugers Arch **452**(5):
413 598-607.

414 North, R. A. (2002). "Molecular physiology of P2X receptors." Physiol Rev **82**(4): 1013-1067.

415 Puchalowicz, K., I. Baranowska-Bosiacka, V. Dziedziejko and D. Chlubek (2015). "Purinergic signaling
416 and the functioning of the nervous system cells." Cell Mol Biol Lett **20**(5): 867-918.

417 Qin, S., F. Jiang, Y. Zhou, G. Zhou, P. Ye and Y. Ji (2017). "Local knockdown of Nav1.6 relieves pain
418 behaviors induced by BmK I." Acta Biochim Biophys Sin (Shanghai) **49**(8): 713-721.

419 Skaper, S. D., P. DeBetto and P. Giusti (2010). "The P2X7 purinergic receptor: from physiology to
420 neurological disorders." FASEB J **24**(2): 337-345.

421 Sperlagh, B., E. S. Vizi, K. Wirkner and P. Illes (2006). "P2X7 receptors in the nervous system." Prog
422 Neurobiol **78**(6): 327-346.

423 Wu, B., Y. Ma, Z. Yi, S. Liu, S. Rao, L. Zou, S. Wang, Y. Xue, T. Jia, S. Zhao, L. Shi, L. Li, H. Yuan and S. Liang
424 (2017). "Resveratrol-decreased hyperalgesia mediated by the P2X7 receptor in gp120-treated rats."
425 Mol Pain **13**: 1744806917707667.

426 Wu, B., L. Peng, J. Xie, L. Zou, Q. Zhu, H. Jiang, Z. Yi, S. Wang, Y. Xue, Y. Gao, G. Li, S. Liu, C. Zhang, G. Li,
427 S. Liang and H. Xiong (2017). "The P2X7 receptor in dorsal root ganglia is involved in HIV
428 gp120-associated neuropathic pain." Brain Res Bull **135**: 25-32.

429 Xie, J., S. Liu, B. Wu, G. Li, S. Rao, L. Zou, Z. Yi, C. Zhang, T. Jia, S. Zhao, G. Schmalzing, R. Hausmann, H.
430 Nie, G. Li and S. Liang (2017). "The protective effect of resveratrol in the transmission of neuropathic
431 pain mediated by the P2X7 receptor in the dorsal root ganglia." Neurochem Int **103**: 24-35.

432 Xie, W., J. A. Strong and J. M. Zhang (2009). "Early blockade of injured primary sensory afferents
433 reduces glial cell activation in two rat neuropathic pain models." Neuroscience **160**(4): 847-857.

434 Zhang, X., Y. Chen, C. Wang and L. Y. Huang (2007). "Neuronal somatic ATP release triggers
435 neuron-satellite glial cell communication in dorsal root ganglia." Proc Natl Acad Sci U S A **104**(23):
436 9864-9869.

437 Zhou, J., X. Zhang, Y. Zhou, B. Wu and Z. Y. Tan (2019). "Up-regulation of P2X7 Receptors Contributes to
438 Spinal Microglial Activation and the Development of Pain Induced by BmK-I." Neurosci Bull.

439

440

441

442 **Figure Legends:**

443 **Fig.1: BmK I induces P2X7R activation in DRG**

444 The spatiotemporal distribution of P2X7R in DRG following the injection of BmK I (A-K).
445 Compared with the saline group (A,F), BmK I-treated groups (B-E) showed largely increased
446 P2X7R immunoreactivity in the ipsilateral DRGs. Increased ipsilateral P2X7R immunoreactivity
447 began at 2 h and peaked at 4 h following the administration of BmK I. Scale bar: (A-J) 100 μ m (K).
448 The histogram represents the statistic results of P2X7R expression in bilateral DRG.***p< 0.001,
449 **p< 0.01, and *p< 0.05 (n=3), when compared with control group by Two-way ANOVA,
450 Dunnett's post hoc test, Error bars indicate SEM (K). Western blot analysis of P2X7R in DRG after
451 intraplantar injection of BmK I(G,H). Representative Western blots show levels of P2X7R and
452 β -actin in both ipsilateral (G) and contralateral (H) sides of DRG, histograms represent the mean
453 levels with respect to each control group at different time points after intraplantar BmK I injection.
454 QPCR results of P2X7R mRNA expression on the ipsilateral (N) and contralateral (O) sides of
455 spinal cord. The data are presented as mean \pm S.E.M. of three rats per group. *p<0.05, **p<0.01,
456 ***p<0.001, when compared with control group and assessed using a One-way ANOVA,
457 Dunnett's post hoc test.

458

459 **Fig 2: Cellular localization of P2X7R immunoreactivity in DRG.**

460 Double immunofluorescence of P2X7R in DRG after intraplantar administration of BmK I. (A-F)
461 (A, D) showed the positive staining of P2X7R while (B, E) showed the positive staining of GFAP.
462 (C, F) showed the colocalization of P2X7R with GFAP. Scale bars: (A-F) 50 μ m;

463

464

465 **Fig 3: Effects of BmK I on the release of IL-1 β in DRG.**

466 Immunoreactivity of IL-1 β in the rat DRG following the injection of BmK I. (A-F) Compared
467 with the saline group (A-B), bilateral IL-1 β immunoreactivity of DRG increased significantly in

468 BmK I-treated rats (C-F). White open squares (in C, D) indicate the corresponding scope of the
469 amplified images (E, F) in the confocal images. Scale bars: (A-D) 100 μm ; (E, F) 50 μm . Western
470 blot analysis of IL-1 β in DRG in the presence of BmK I (G, H). (G) and (H), representative
471 Western blots showing levels of IL-1 β and β -actin in both ipsilateral (G) and contralateral (H)
472 sides of DRG, histograms represent the mean levels with respect to each control group at different
473 time points after intraplantar BmK I injection. The data are presented as mean \pm S.E.M. * p <0.05,
474 ** p <0.01, *** p <0.001 (n=3), when compared with control group and assessed using a one-way
475 ANOVA, followed by Dunnett's post hoc test.

476

477 **Fig 4: P2X7R antagonist A-438079 inhibits the BmK I-induced pain.**

478 (A) Attenuated spontaneous pain behavior was observed after pretreatment of 100 μM A-438079
479 (i.p.) 30 min before local administration of BmK I. Total number of paw flinches (B) was
480 suppressed by the pretreatment of A-438079 within the 2 h following the injection of BmK I.
481 A-438079 reduced both ipsilateral (C) and contralateral (D) mechanical hypersensitivity as well as
482 ipsilateral (E) thermal hypersensitivity. A-438079 had no effect on contralateral basal thermal
483 latency values (F). * p <0.05, ** p <0.01, *** p <0.001 by one-way ANOVA, Dunnett's post hoc test
484 and Two-way ANOVA, Bonfereoni's post hoc test, when compared with saline vehicle group. n=6
485 for each group.

486

487

Fig. 1 [Download full resolution image](#)




Fig. 2 [Download full resolution image](#)




Fig. 3 [Download full resolution image](#)




Fig. 4 [Download full resolution image](#)

